Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib (LASOR)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 3, 2008
Last updated: October 15, 2015
Last verified: October 2015
There is no available data on the clinical benefit of dose escalation for patients with suboptimal response to imatinib, and patients may still improve their response with continuation of therapy at the standard dose as shown in the IRIS trial after 5 years of follow-up. However, there is no data yet regarding the potential benefit of using nilotinib in the group of patients with suboptimal response. In this study, the efficacy of nilotinib 400mg BID will be compared to imatinib 600mg QD.

Condition Intervention Phase
Chronic Myelogenous Leukemia
Drug: nilotinib
Drug: imatinib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase Lll Study of Imatinib Dose Optimization Compared With Nilotinib in Patients With Chronic Myelogenous Leukemia and Suboptimal Response to Standard-dose Imatinib

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Percentage of Participants With Complete Cytogenetic Response (CCyR) [ Time Frame: 6 months ]
    CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.

Secondary Outcome Measures:
  • Percentage of Participants With Major Molecular Response (MMR) [ Time Frame: 12 and 24 months ]
    MMR was defined as having a fusion gene of the Bcr and Abl genes of (BCR-ACL) less than or equal to 0.1% on the International Scale (IS).

  • Percentage of Participants With CCyr [ Time Frame: 12 and 24 months ]
    CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.

  • Time to CCyR [ Time Frame: 24 months ]
    Time to CCyR was defined as time from date of randomization to date of first documented CCyR.

  • Duration of CCyR [ Time Frame: 24 months ]
    Duration of CCyR was defined as time from the date of ransomization to the date of first loss of CCyR or death, whichever came first.

  • Progression-Free Survival (PFS) [ Time Frame: 24 months ]
    PFS was defined as the time from the date of randomization to the date of documented disease progression to accelerated phase or blast crisis (AP/BC), or death due to any cause.

  • Event-Free Survival (EFS) [ Time Frame: 24 months ]
    EFS was defined as the time from the date of randomization to the date of the first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of Partial Cytogenetic Response (PCyR), loss of CCyR, death on treatment or progression to AP/BC.

  • Overall Survival (OS) [ Time Frame: 24 months ]
    OS was defined as time from date of randomization to the date of the death.

Enrollment: 191
Study Start Date: May 2009
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nilotinib
Participants received 400 mg nilotinib twice daily (BID).
Drug: nilotinib
Supplied as 200 mg tablets
Other Name: Tasigna
Active Comparator: Imatinib
Participants received 600 mg imatinib once daily (QD).
Drug: imatinib
Supplied as 100 mg and 400 mg tablets
Other Name: Gleevec/Glivec

Detailed Description:
The comparative efficacy between imatinib dose escalation (600 mg QD) and nilotinib (400 mg BID), in terms of CCyR after 6 months, for patients with CML in chronic phase with suboptimal response to imatinib standard dose will be determined.

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Male or female ≥ 18 years old;
  2. ECOG of 0, 1, or 2;
  3. Ph+ CML in CP defined as:

    • <15% blasts in peripheral blood or bone marrow;
    • <30% blasts + promyelocytes in peripheral blood or bone marrow;
    • <20% basophils in the peripheral blood;

      •≥100x109/L (≥ 100,000/mm3) platelets;

    • no evidence of extramedullary leukemia involvement, with the exception of hepatosplenomegaly;
  4. SoR to 400 mg imatinib, defined as (min of 20 metaphases):

    • No cytogenetic response at ≥ 3 to <6 months (> 95% Ph+ metaphases);or
    • No PCyR at ≥ 6 to <12 months (36 to 95% Ph+ metaphases on bone marrow); or
    • No CCyR at ≥ 12 to <18 months (1 to 35% Ph+ metaphases on bone marrow); Confirmation of SoR by FISH is allowed if BMK is done outside the screening window up to 4 wks.
  5. 400mg/daily imatinib (no higher doses) for at least 3months but no longer than 18 months;
  6. Previous use of IFN, taken prior to imatinib treatment, is allowed at a maximum of 90 days unless reason for switch from IFN to imatinib was intolerance.
  7. Parameters must be present:

    • Creatinine <2.0 X ULN
    • Total bilirubin <1.5 X ULN (< 3.0 X ULN if related to disease);
    • SGOT and SGPT < 2.5 X ULN;
    • Serum lipase ≤1.5 X ULN;
    • Alkaline phosphatase ≤2.5 X ULN
    • Serum potassium, phosphorus, magnesium and calcium ≥ LLN or corrected to WNL with supplements prior to first dose of study drug;
  8. Written informed consent prior to any study procedures being performed.

Exclusion criteria:

  1. Prior accelerated phase including clonal evolution or blast crisis CML;
  2. Prior therapy with imatinib in combination with any other CML drug other than Hydroxyurea and/or Anagrelide;

4.Imatinib therapy started more than 12 months after the date of the original diagnosis; 5.Unable to tolerate imatinib at 400mg; 6.Previous treatment with any other tyrosine kinase inhibitor except Glivec and/or CML therapy other than IFN, hydroxyurea, and /or anagrelide; 7.Myelotoxicity ≥ Grade 2 present at the time of randomization, 8.Previously documented T315I mutations; 9.Impaired cardiac function including one of these:

  • Long QT syndrome or family history of long QT syndrome
  • Clinically significant resting brachycardia (<50 bpm)
  • QTcF >450 msec on screening ECG (using the QTcF formula). If QTc >450 and electrolytes are not with normal ranges, electrolytes should be corrected and then the patient rescreened for QTc to certify QTc <450 msec;
  • Myocardial infarction ≤ 12 months prior to the first dose of study drug;
  • Other clinically significant heart disease (e.g., CHF, uncontrolled hypertension, unstable angina, significant ventricular or atrial tachyarrhythmias) 10. Impairment of GI function or disease that may significantly alter the absorption of study drug; 11. Treated with strong CYP3A4 inhibitors that cannot be either discontinued or switched to a different medication prior to starting study drug; 12.Currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug; 13.History of previous acute pancreatitis within one year of study entry or medical history of chronic pancreatitis; 14.Known cytopathologically confirmed CNS 15.Women who are pregnant, breast feeding or of a childbearing potential without a negative urine pregnancy test at screening. Female patients of childbearing potential unwilling to use effective contraceptive precautions throughout the trial and for 3 months post trial end. Post-menopausal women must be ammenorrheic for at least 12 months to be considered of non-childbearing potential; 16. History of another primary malignancy that is currently clinically significant or currently requires active intervention; 17.Any other clinically significant medical or surgical condition which, according to investigators' discretion, should preclude participation; 18.Use of investigational agent within 28 days prior to enrollment; 19.Patients unwilling or unable to comply with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00802841

  Show 56 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00802841     History of Changes
Other Study ID Numbers: CAMN107A2404
2008-007054-35 ( EudraCT Number )
Study First Received: December 3, 2008
Results First Received: July 15, 2015
Last Updated: October 15, 2015

Keywords provided by Novartis:
Chronic Phase
Suboptimal Response

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017